Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Genitourinary 3Thoracic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 2Pleural Effusion, Malignant 1Ovarian Neoplasms 1Mesothelioma 1Breast Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Valacyclovir × Thoracic × Clear all
NCT03131037 2025-07-11

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Candel Therapeutics, Inc.

Phase 1 Completed
12 enrolled
Thoracic

Lung Neoplasms

NCT01997190 2023-08-25

MpeTK01

Candel Therapeutics, Inc.

Phase 1 Completed
19 enrolled
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡